UY34271A - Anticuerpos anti-tie2 y usos de los mismos - Google Patents
Anticuerpos anti-tie2 y usos de los mismosInfo
- Publication number
- UY34271A UY34271A UY0001034271A UY34271A UY34271A UY 34271 A UY34271 A UY 34271A UY 0001034271 A UY0001034271 A UY 0001034271A UY 34271 A UY34271 A UY 34271A UY 34271 A UY34271 A UY 34271A
- Authority
- UY
- Uruguay
- Prior art keywords
- same
- tie2 antibodies
- tie2
- antibodies
- escanear
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona anticuerpos que se unen a Tie2 y métodos de uso de los mismos. Según ciertas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a Tie2 humano y bloquean la interacción 5 entre Tie2 y uno o más ligandos de Tie2, tales como angiopoyetina 1 (Ang1), angiopoyetina 2 (Ang2), angiopoyetina 3 (Ang3) y/o angiopoyetina 4 (Ang4). Los anticuerpos de la invención son útiles, entre otros, para el tratamiento de enfermedades y trastornos asociados a una o más actividades biológicas de Tie2, que incluyen la angiogénesis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161525308P | 2011-08-19 | 2011-08-19 | |
US201261587213P | 2012-01-17 | 2012-01-17 | |
US201261674405P | 2012-07-23 | 2012-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34271A true UY34271A (es) | 2013-02-28 |
Family
ID=46785799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034271A UY34271A (es) | 2011-08-19 | 2012-08-17 | Anticuerpos anti-tie2 y usos de los mismos |
Country Status (15)
Country | Link |
---|---|
US (4) | US9017670B2 (es) |
EP (2) | EP3415533A1 (es) |
JP (2) | JP6333174B2 (es) |
KR (1) | KR20140054303A (es) |
CN (2) | CN103874709B (es) |
AR (1) | AR087567A1 (es) |
AU (1) | AU2012299195B9 (es) |
CA (1) | CA2844306C (es) |
ES (1) | ES2694411T3 (es) |
IL (1) | IL230529A (es) |
IN (1) | IN2014CN02025A (es) |
MX (1) | MX359833B (es) |
SG (1) | SG10201606872TA (es) |
UY (1) | UY34271A (es) |
WO (1) | WO2013028442A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3415533A1 (en) | 2011-08-19 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Anti-tie2 antibodies uses thereof |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
RS59000B1 (sr) * | 2013-11-01 | 2019-08-30 | Regeneron Pharma | Intervencije zasnovane na angiopoietinu za lečenje cerebralne malarije |
EP3170841A4 (en) | 2014-07-15 | 2018-01-10 | Astellas Pharma Inc. | NOVEL ANTI-HUMAN Tie2 ANTIBODY |
WO2016115092A1 (en) * | 2015-01-12 | 2016-07-21 | La Jolla Institute For Allergy And Immunology | Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever |
US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
US11397183B2 (en) | 2017-02-09 | 2022-07-26 | Fred Hutchinson Cancer Center | Biomarkers and uses thereof for selecting immunotherapy intervention |
WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
WO2019235856A1 (ko) * | 2018-06-07 | 2019-12-12 | 기초과학연구원 | Tie2에 결합하는 항체 및 이의 용도 |
KR20190139148A (ko) * | 2018-06-07 | 2019-12-17 | 기초과학연구원 | Tie2에 결합하는 항체 및 이의 용도 |
JP2021529556A (ja) | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. | 抗腫瘍アンタゴニスト |
CN114340735A (zh) | 2019-06-28 | 2022-04-12 | 璟尚生物制药公司 | 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂 |
SG11202111656WA (en) * | 2019-08-14 | 2021-11-29 | Pharmabcine Inc | Anti-tie2 antibody and use thereof |
AU2020385991A1 (en) * | 2019-11-21 | 2022-06-23 | Unity Biotechnology | Antibodies directed to Tie-2 and methods of use |
CA3169967A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
EP4328242A1 (en) * | 2021-04-23 | 2024-02-28 | Neortesbio Inc. | Antibody specifically binding to angiopoietin-2, or fragment thereof |
US20220389120A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
WO2023137395A1 (en) * | 2022-01-13 | 2023-07-20 | Ingenia Therapeutics Inc. | Vegf and tie2-binding fusion protein and uses thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
AU4651893A (en) | 1992-06-26 | 1994-01-24 | Immunex Corporation | Novel tyrosine kinase |
US5681714A (en) | 1992-07-30 | 1997-10-28 | Mount Sinai Hospital Corporation | Nucleic acid encoding tek receptor tyrosine kinase |
WO1995013387A1 (en) | 1993-11-12 | 1995-05-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tie-2, a novel receptor tyrosine kinase |
AUPM379494A0 (en) | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - ii |
US20030040463A1 (en) * | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
US6365154B1 (en) | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
US6376653B1 (en) | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
DE60027564T3 (de) | 1999-06-07 | 2009-07-23 | Immunex Corp., Thousand Oaks | Tek-antagonisten |
US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
AU782067B2 (en) * | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
BR0111861A (pt) | 2000-06-23 | 2003-12-23 | Schering Ag | Combinações e composições que interferem com função receptora vegf/vegf e angiopoietina/tie e seu uso(ii) |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20040101920A1 (en) * | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7485297B2 (en) | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
JP2008501677A (ja) * | 2004-06-04 | 2008-01-24 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療する方法 |
WO2006005361A1 (en) * | 2004-07-13 | 2006-01-19 | Centre National De La Recherche Scientifique | Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses |
WO2006020706A2 (en) * | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
US7745641B2 (en) | 2005-04-19 | 2010-06-29 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
CA2693383C (en) | 2006-10-27 | 2017-03-28 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
WO2010011242A2 (en) * | 2008-03-24 | 2010-01-28 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnoisis of systemic anthrax infection |
US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20130188013A1 (en) * | 2011-07-22 | 2013-07-25 | Qualcomm Incorporated | Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode |
EP3415533A1 (en) | 2011-08-19 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Anti-tie2 antibodies uses thereof |
-
2012
- 2012-08-16 EP EP18182258.6A patent/EP3415533A1/en not_active Withdrawn
- 2012-08-16 KR KR1020147007328A patent/KR20140054303A/ko not_active Application Discontinuation
- 2012-08-16 US US13/586,911 patent/US9017670B2/en active Active
- 2012-08-16 SG SG10201606872TA patent/SG10201606872TA/en unknown
- 2012-08-16 CN CN201280040426.9A patent/CN103874709B/zh not_active Expired - Fee Related
- 2012-08-16 EP EP12753873.4A patent/EP2744827B1/en active Active
- 2012-08-16 ES ES12753873.4T patent/ES2694411T3/es active Active
- 2012-08-16 WO PCT/US2012/051038 patent/WO2013028442A1/en active Application Filing
- 2012-08-16 AR ARP120103012A patent/AR087567A1/es unknown
- 2012-08-16 CA CA2844306A patent/CA2844306C/en active Active
- 2012-08-16 MX MX2014001738A patent/MX359833B/es active IP Right Grant
- 2012-08-16 CN CN201611002573.3A patent/CN106963946A/zh active Pending
- 2012-08-16 JP JP2014526193A patent/JP6333174B2/ja active Active
- 2012-08-16 AU AU2012299195A patent/AU2012299195B9/en active Active
- 2012-08-17 UY UY0001034271A patent/UY34271A/es unknown
-
2014
- 2014-01-19 IL IL230529A patent/IL230529A/en not_active IP Right Cessation
- 2014-03-17 IN IN2025CHN2014 patent/IN2014CN02025A/en unknown
-
2015
- 2015-03-27 US US14/671,494 patent/US9546218B2/en active Active
-
2016
- 2016-12-09 US US15/373,903 patent/US10023641B2/en active Active
-
2017
- 2017-05-17 JP JP2017097857A patent/JP6654165B2/ja active Active
-
2018
- 2018-06-13 US US16/007,399 patent/US10442864B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34271A (es) | Anticuerpos anti-tie2 y usos de los mismos | |
UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
TWD180147S (zh) | 淨水器 | |
UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
ECSP14005975A (es) | Anticuerpos anti-PHF-tau y sus usos | |
UY34539A (es) | Heteroarilos y usos de los mismos | |
CL2016001432A1 (es) | Nuevos anticuerpos anti-dpep3 y métodos de uso | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
UY34603A (es) | Anticuerpos anti-asic-1 y usos de los mismos | |
CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
ECSP13012786A (es) | Anticuerpos anti-pcsk9 y métodos de uso | |
CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
UY34632A (es) | Compuestos de oxazolidin- 2- ona y usos de los mismos | |
UY34018A (es) | Derivados glucósidos y usos de los mismos | |
UY34764A (es) | Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso | |
UY33946A (es) | Derivados de c4-monometil triterpenoides y sus métodos de uso | |
UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
UY34502A (es) | Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio | |
CR20140212A (es) | Anticuerpos anti-htra1 y métodos de uso | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
CO6940376A2 (es) | Anticuerpos anti-psgl-1 y usos de los mismos |